Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects
- The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4P-Pharma SASAccuitis Pharmaceuticals Inc
AegleStem Therapeutics
AISA Pharma Inc
Amgen Inc
AnaMar AB
Annji Pharmaceutical Co Ltd
APIE Therapeutics Inc
Arxx Therapeutics AS
AstraZeneca Plc
Astria Therapeutics Inc
Atlantic Healthcare Plc
aTyr Pharma Inc
Aurora Research Institute LLC
Avotres Inc
Bausch Health Companies Inc
Beijing Toll Biotech Co Ltd
Belarusian State Medical University
Biocad
Biogen Inc
Biomendics LLC
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Cantargia AB
Castle Creek Biosciences Inc
Celdara Medical LLC
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chongqing Precision Biotech Co Ltd
Civi Biopharma Inc
Corvus Pharmaceuticals Inc
Coya Therapeutics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Cureveda LLC
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Drexel University
Edesa Biotech Inc
Eluciderm Inc
Eydis Bio Inc
F. Hoffmann-La Roche Ltd
FibroBiologics Inc
Foresee Pharmaceuticals Co Ltd
Friedrich-Alexander-University Erlangen-Nuremberg
Genentech USA Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gesynta Pharma AB
GNI Group Ltd
GSK plc
Guangzhou Henovcom Bioscience Co Ltd
Horizon Therapeutics Plc
HotSpot Therapeutics Inc
Huabo Biopharm (Shanghai) Co Ltd
Iltoo Pharma
ImmuneID Inc
Jiangsu Ruiyuan Biotechnology Co Ltd
Johnson & Johnson
Kymera Therapeutics Inc
Kyowa Kirin Co Ltd
Kyungpook National University
Kyverna Therapeutics Inc
Lassen Therapeutics 1 Inc
LightOx Ltd
Link Genomics Inc
Luminary Therapeutics Inc
Mallinckrodt Plc
Maruho Co Ltd
MDI Therapeutics Inc
Medsenic SAS
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Nobelpharma Co Ltd
Ono Pharmaceutical Co Ltd
Opsidio LLC
Panorama Research Institute
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals Inc
Peptinov SAS
Pfizer Inc
Pharmosa Biopharm Inc
Queensland University of Technology
RadBio
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Ribomic Inc
Ribon Therapeutics Inc
Riptide Bioscience Inc
Rubedo Life Sciences Inc
Scopus BioPharma Inc
Seagen Inc
Shanghai YaKe Biotechnology Co Ltd
Signablok Inc
Takeda Pharmaceutical Co Ltd
Thirona Bio Inc
Timber Pharmaceuticals Inc
Tvardi Therapeutics Inc
University of California
University of Tennessee Health Science Center
Ventus Therapeutics Inc
Zura Bio Ltd